The United States is in the midst of its worst year yet for cyclosporiasis, an intestinal illness caused by a parasite ...
Summit Therapeutics signs agreement to sell phase III asset ridinilazole to Biossil: Miami Wednesday, July 15, 2026, 18:00 Hrs [IST] Summit Therapeutics Inc., a biopharmaceutical ...
Health officials are warning that symptoms, including explosive diarrhea, may not appear immediately after exposure.
Today the first participants were enrolled in a trial testing Gilead Sciences' experimental antiviral drug obeldesivir as ...
Nigeria has recorded 221 deaths from Lassa fever since the beginning of the year, now surpassing the 190 fatalities recorded ...
Summit Therapeutics (SMMT) stock gains as the company agrees to sell its antibiotic candidate ridinilazole to Canada's ...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that a poster ...
A microscopic parasite is making thousands of Americans sick this summer, and public health officials are still figuring out ...
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigational Phase III precision antibiotic ...
Texas has 68 confirmed Cyclospora cases as the national count tops 840 in 31 states. The CDC still has not pinpointed the ...
Five innovative companies are challenging industry norms across cancer treatment, agriculture, antibiotics, cybersecurity, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results